The Wegovy Shortage in the UK: What the Evidence Shows

What the official record shows about semaglutide supply

Wegovy's supply difficulties are not rumour — they appear in NHS England's published guidance on weight-management injections, which noted constrained availability and asked prescribers to manage titration carefully. Novo Nordisk, the manufacturer, publicly acknowledged that global demand for semaglutide across its entire portfolio (Ozempic for diabetes, Wegovy for weight management) stretched production facilities beyond their planned output. The MHRA has been monitoring the situation and publishing medicine shortage protocols, which instruct prescribers on clinical management when a licensed product is unavailable.

The pattern has been uneven by dose. Lower starter doses have generally been easier to obtain than higher maintenance strengths; the 1.7mg and 2.4mg pens caused the longest waits for many patients. Novo Nordisk has given phased supply restoration timelines, and the position in mid-2026 is materially better than in 2023 and 2024, though constraints have not disappeared entirely. If you want to understand your current options, the current state of the Wegovy shortage is covered in more detail on a dedicated page.

NHS England's guidance on weight-management injections, published for both prescribers and patients, remains the most authoritative UK source on how shortage periods should be handled clinically. It is worth reading alongside any information from your pharmacy or clinic.

Why shortages happen with newly licensed medicines like this

When a medicine transitions from clinical trials to widespread commercial supply, manufacturers calibrate production against modelled demand. Wegovy's real-world uptake, accelerated by significant media attention and a NICE recommendation for semaglutide (TA875), far exceeded those projections in the UK and across Europe. That gap between production capacity and patient demand is the root cause of the ongoing semaglutide shortage that many UK patients encountered.

The STEP 1 trial, published in the New England Journal of Medicine, reported around 15% average weight reduction at the 2.4mg maintenance dose over 68 weeks. Results of that scale, widely covered in the press, drove demand well beyond what any single manufacturer had planned for. A second factor: semaglutide is also prescribed as Ozempic for type 2 diabetes, and any production constraints ripple across both products simultaneously.

Novo Nordisk has invested heavily in manufacturing expansion. That takes time, biological medicines are not produced the way tablets are. Our semaglutide overview explains how the medicine works and why its production process is more complex than conventional oral drugs.

What a shortage means if you are already on Wegovy

If your pharmacy cannot fulfil your prescription, the right first step is to contact your prescriber, not to seek alternative sources online. NHS England's guidance is explicit that clinical decisions about pausing or adjusting treatment belong with the prescriber, not with the patient acting alone. Stopping abruptly after a period of treatment can affect the results you have achieved; a prescriber can advise whether to wait, stay at your current dose for longer, or discuss other options.

It is also worth knowing that a shortage of the injection does not necessarily mean all forms of semaglutide for weight management are unavailable. The MHRA approved the first oral GLP-1 medicine licensed for weight management in the UK on 11 June 2026, Wegovy tablets, a once-daily option reaching a 25mg maintenance dose. Whether that or any alternative suits your circumstances is a question for a prescriber. If a gap in supply has you wondering whether it makes sense to take Wegovy for only a short time, our dedicated page explores what the evidence says about briefer courses of treatment, and you can also read about whether using Wegovy short term is a viable approach if a supply gap makes a longer commitment uncertain right now.

One question our prescribers hear regularly: can you simply order from another source to bridge a gap? The honest answer is that you should not. The MHRA has seized large quantities of fake weight-loss pens sold without a prescription; some contained insulin rather than semaglutide, and hospitalisations have followed. You can verify any online pharmacy on the GPhC register before placing an order anywhere.

Choosing a private route during a shortage period

Private pharmacies and clinics source medicines through the licensed UK supply chain, just as NHS pharmacies do. A shortage that affects NHS supply will generally affect private supply too, because all legitimate UK pharmacies draw from the same MHRA-regulated wholesale network. Any private provider claiming guaranteed, unlimited Wegovy stock during a documented shortage period is worth scrutinising carefully.

What a private route can offer is speed and flexibility. There is no waiting list for a consultation, and a prescriber can discuss your options, including whether tirzepatide (Mounjaro), which works on two receptor pathways rather than one, might suit your circumstances. In the SURMOUNT-5 trial, tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks. That is clinical information, not a recommendation; the right medicine for you is decided after a proper assessment.

If you want to understand how private treatment costs compare, our Wegovy price comparison guide sets out what a legitimate private prescription typically includes. And if you are simply unsure what is available to you right now, our weight-loss treatment overview covers each licensed option in plain terms. When you are ready to talk to a prescriber, you can start your free consultation at any point, same-day clinical review, no waiting list.